BioCentury | Oct 9, 2014
Cover Story

Invigorating IVIG

...has a sialylated IVIG obtained from its acquisition of the assets from Jeffrey Ravetch's startup, Virdante Pharmaceuticals Inc....
BioCentury | Feb 6, 2012
Finance

Venturing home

...million up front and up to $120 million in milestones; and autoimmune and inflammation company Virdante Pharmaceuticals Inc....
BioCentury | Dec 12, 2011
Company News

Momenta, Virdante Pharmaceuticals deal

...be advanced into the clinic." Details were not disclosed. Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Cambridge, Mass. Virdante Pharmaceuticals Inc....
BioCentury | Mar 8, 2010
Emerging Company Profile

Virdante: Superpowering Sialylation

...globulin products provide symptomatic relief for autoimmune and inflammatory conditions when given at high doses. Virdante Pharmaceuticals Inc....
...have little or no effect." COMPANIES OR INSTITUTIONS MENTIONED Rockefeller University , New York, N.Y. Virdante Pharmaceuticals Inc....
BioCentury | Mar 8, 2010
Emerging Company Profile

Sidebar: Virdante Pharmaceuticals Inc.

Virdante Pharmaceuticals Inc. Cambridge, Mass. Technology: Sialic Switch technology to improve anti-inflammatory properties of antibodies Disease focus: Autoimmune, inflammation Clinical status: Preclinical Founded: 2007 by Jeffrey Ravetch University collaborators: Not disclosed Corporate partners: Not disclosed...
BioCentury | Nov 2, 2009
Company News

Virdante Pharmaceuticals board of directors update

Virdante Pharmaceuticals Inc. , Cambridge, Mass. Business: Autoimmune, Inflammation Appointed: Eric Aguiar, partner at Thomas, McNerney & Partners; and L. Patrick Gage, former president of Wyeth Research at Wyeth (now part of Pfizer Inc. ), as...
BioCentury | Nov 2, 2009
Financial News

Virdante Pharmaceuticals completes venture financing

Virdante Pharmaceuticals Inc. , Cambridge, Mass. Business: Autoimmune, Inflammation Date completed: 10/29/09 Type: Venture financing Raised: $47.8 million Investors: Clarus Ventures; Venrock; Thomas, McNerney & Partners; Osage Partners; MedImmune Ventures; Biogen Idec New Ventures Note: The...
BioCentury | Oct 30, 2009
Financial News

Virdante extends financing

Virdante Pharmaceuticals Inc. (Cambridge, Mass.) raised an undisclosed amount in an extension of a series A round, bringing the total raised in the round to $47.8 million. New investor Thomas, McNerney led the extension, which...
Items per page:
1 - 8 of 8
BioCentury | Oct 9, 2014
Cover Story

Invigorating IVIG

...has a sialylated IVIG obtained from its acquisition of the assets from Jeffrey Ravetch's startup, Virdante Pharmaceuticals Inc....
BioCentury | Feb 6, 2012
Finance

Venturing home

...million up front and up to $120 million in milestones; and autoimmune and inflammation company Virdante Pharmaceuticals Inc....
BioCentury | Dec 12, 2011
Company News

Momenta, Virdante Pharmaceuticals deal

...be advanced into the clinic." Details were not disclosed. Momenta Pharmaceuticals Inc. (NASDAQ:MNTA), Cambridge, Mass. Virdante Pharmaceuticals Inc....
BioCentury | Mar 8, 2010
Emerging Company Profile

Virdante: Superpowering Sialylation

...globulin products provide symptomatic relief for autoimmune and inflammatory conditions when given at high doses. Virdante Pharmaceuticals Inc....
...have little or no effect." COMPANIES OR INSTITUTIONS MENTIONED Rockefeller University , New York, N.Y. Virdante Pharmaceuticals Inc....
BioCentury | Mar 8, 2010
Emerging Company Profile

Sidebar: Virdante Pharmaceuticals Inc.

Virdante Pharmaceuticals Inc. Cambridge, Mass. Technology: Sialic Switch technology to improve anti-inflammatory properties of antibodies Disease focus: Autoimmune, inflammation Clinical status: Preclinical Founded: 2007 by Jeffrey Ravetch University collaborators: Not disclosed Corporate partners: Not disclosed...
BioCentury | Nov 2, 2009
Company News

Virdante Pharmaceuticals board of directors update

Virdante Pharmaceuticals Inc. , Cambridge, Mass. Business: Autoimmune, Inflammation Appointed: Eric Aguiar, partner at Thomas, McNerney & Partners; and L. Patrick Gage, former president of Wyeth Research at Wyeth (now part of Pfizer Inc. ), as...
BioCentury | Nov 2, 2009
Financial News

Virdante Pharmaceuticals completes venture financing

Virdante Pharmaceuticals Inc. , Cambridge, Mass. Business: Autoimmune, Inflammation Date completed: 10/29/09 Type: Venture financing Raised: $47.8 million Investors: Clarus Ventures; Venrock; Thomas, McNerney & Partners; Osage Partners; MedImmune Ventures; Biogen Idec New Ventures Note: The...
BioCentury | Oct 30, 2009
Financial News

Virdante extends financing

Virdante Pharmaceuticals Inc. (Cambridge, Mass.) raised an undisclosed amount in an extension of a series A round, bringing the total raised in the round to $47.8 million. New investor Thomas, McNerney led the extension, which...
Items per page:
1 - 8 of 8